Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.378
+0.001 (0.16%)
At close: Mar 6, 2026, 4:00 PM EST
0.396
+0.018 (4.87%)
After-hours: Mar 6, 2026, 7:53 PM EST
Sangamo Therapeutics Stock Forecast
SGMO's stock price has decreased by -56.85% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Sangamo Therapeutics stock have an average target of 5.75, with a low estimate of 1.00 and a high estimate of 10. The average target predicts an increase of 1,423.18% from the current stock price of 0.38.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sangamo Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +2,549.01% | Feb 10, 2026 |
| Barclays | Barclays | Buy → Hold Downgrades $5 → $1 | Buy → Hold | Downgrades | $5 → $1 | +164.90% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +2,549.01% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +2,549.01% | Jun 24, 2025 |
| Barclays | Barclays | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +1,224.50% | May 14, 2025 |
Financial Forecast
Revenue This Year
60.57M
from 57.80M
Increased by 4.79%
Revenue Next Year
49.23M
from 60.57M
Decreased by -18.73%
EPS This Year
-0.34
from -0.49
EPS Next Year
-0.28
from -0.34
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 131.6M | 119.7M | ||||
| Avg | 60.6M | 49.2M | ||||
| Low | 34.0M | 8.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 127.6% | 97.6% | ||||
| Avg | 4.8% | -18.7% | ||||
| Low | -41.2% | -86.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.13 | -0.11 | ||||
| Avg | -0.34 | -0.28 | ||||
| Low | -0.42 | -0.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.